Choline acetyltransferase activity and striatal dopamine receptors in Parkinson's disease in relation to cognitive impairment

No abstract is available for this paper.

• Publication year

  2001

• Venue

  Acta Neuropathologica

• Publication date

  2001-08-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1007/s004010100372
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar

• No claims are published for this paper.

• No concepts are published for this paper.

• Cortical Lewy bodies and Alzheimer-type changes in patients with Parkinson’s disease

  1998influential reference
• Association between decline in brain dopamine activity with age and cognitive and motor impairment in healthy individuals.

  1998cited by this paper
• Functional effects of striatal dysfunction in Parkinson disease.

  1997cited by this paper
• Dementia with Lewy Bodies Versus Pure Alzheimer Disease: Differences in Cognition, Neuropathology, Cholinergic Dysfunction, and Synapse Density

  1997cited by this paper
• D2 dopamine receptors and personality traits

  1997cited by this paper
• Neocortical Lewy Body Counts Correlate with Dementia in the Lewy Body Variant of Alzheimer's Disease

  1996cited by this paper
• Consensus guidelines for the clinical and pathologic diagnosis of dementia with Lewy bodies (DLB)

  1996cited by this paper
• Historical review of research on functions of basal ganglia.

  1996cited by this paper
• Increased density of dopamine D2 receptors in the putamen, but not in the caudate nucleus in early Parkinson's disease: a PET study with [11C]raclopride.

  1995cited by this paper
• Neocortical cholinergic activities differentiate Lewy body dementia from classical Alzheimer's disease.

  1994cited by this paper
• [11C]raclopride and positron emission tomography in previously untreated patients with Parkinson's disease

  1994cited by this paper
• Discordant twins with Parkinson's disease: Positron emission tomography and early signs of impaired cognitive circuits

  1994cited by this paper
• Neurotransmitters in basal ganglia and cortex of Alzheimer's disease with and without Lewy bodies

  1993cited by this paper
• The Lewy-Body Variant of Alzheimer's Disease

  1993cited by this paper
• Cholinergic Transmitter and Neurotrophic Activities in Lewy Body Dementia: Similarity to Parkinson's and Distinction from Alzheimer Disease

  1993cited by this paper
• Asymmetrical pre-synaptic and post-synpatic changes in the striatal dopamine projection in dopa naïve parkinsonism. Diagnostic implications of the D2 receptor status.

  1993cited by this paper
• L-dopa and frontal cognitive function in Parkinson's disease.

  1993cited by this paper
• Striatal D2 receptor status in patients with Parkinson's disease, striatonigral degeneration, and progressive supranuclear palsy, measured with 11C‐raclopride and positron emission tomography

  1992cited by this paper
• The Consortium to Establish a Registry for Alzheimer's Disease (CERAD)

  1991cited by this paper
• Topography, Extent, and Clinical Relevance of Neurochemical Deficits in Dementia of Lewy Body Type, Parkinson's Disease, and Alzheimer's Disease

  1991cited by this paper
• A post-mortem study on striatal dopamine receptors in Parkinson's disease.

  1991influential reference
• The relationship between locomotor disability, autonomic dysfunction, and the integrity of the striatal dopaminergic system in patients with multiple system atrophy, pure autonomic failure, and Parkinson's disease, studied with PET.

  1990cited by this paper
• Age-dependent decline in human brain dopamine D1 and D2 receptors.

  1990cited by this paper
• Cholinergic and Dopaminergic Activities in Senile Dementia of Lewy Body Type

  1990cited by this paper
• Restriction isotyping of human apolipoprotein E by gene amplification and cleavage with HhaI.

  1990cited by this paper
• Diffuse Lewy body disease: correlative neuropathology using anti-ubiquitin immunocytochemistry.

  1989cited by this paper
• A pathological study of the association between Lewy body disease and Alzheimer's disease.

  1989cited by this paper
• Dementia in Parkinson's disease is related to neuronal loss in the medial substantia nigra

  1989cited by this paper
• Brain muscarinic receptor subtypes are differently affected in Alzheimer's disease and Parkinson's disease.

  1989influential reference
• Reductions in acetylcholine and nicotine binding in several degenerative diseases.

  1988cited by this paper
• The relevance of the Lewy body to the pathogenesis of idiopathic Parkinson's disease.

  1988cited by this paper
• Diffuse Lewy body disease and progressive dementia

  1988cited by this paper
• D1 and D2-type dopamine receptors in patients with Parkinson's disease and progressive supranuclear palsy.

  1988cited by this paper
• Genotyping and sequence analysis of apolipoprotein E isoforms.

  1988cited by this paper
• Analysis of radioligand binding experiments. A collection of computer programs for the IBM PC.

  1985cited by this paper
• Cholinergic correlates of cognitive impairment in Parkinson's disease: comparisons with Alzheimer's disease.

  1985influential reference
• Cortical cholinergic deficit in mentally impaired Parkinsonian patients.

  1983influential reference
• A subcortico-cortical cholinergic system is affected in Parkinson's disease.

  1983influential reference
• Brain receptor changes in Parkinson's disease in relation to the disease process and treatment.

  1983cited by this paper
• Alzheimer's disease. Correlation of cortical choline acetyltransferase activity with the severity of dementia and histological abnormalities.

  1982cited by this paper
• A post-mortem study of the cholinergic and GABA systems in senile dementia.

  1982cited by this paper
• Muscarinic binding and choline acetyltransferase activity in Parkinsonian subjects with reference to dementia.

  1982influential reference
• Correlation of cholinergic abnormalities with senile plaques and mental test scores in senile dementia.

  1978cited by this paper
• Selective loss of central cholinergic neurons in Alzheimer's disease.

  1976cited by this paper
• A rapid radiochemical method for the determination of choline acetyltransferase

  1975cited by this paper
• Protein measurement with the Folin phenol reagent.

  1951influential reference

• The basal forebrain cholinergic system as target for cell replacement therapy in Parkinson’s disease

  2024cites this paper
• Motor progression trajectories and risk of mild cognitive impairment in Parkinson's disease: A latent class trajectory model from PPMI cohort

  2024cites this paper
• Neuroanatomical Signature of the Transition from Normal Cognition to MCI in Parkinson's Disease

  2024cites this paper
• Exploring the cognitive implications of traditional and novel subthalamic nucleus deep brain stimulation paradigms in Parkinson’s Disease

  2024cites this paper
• Bacteriophages targeting Enterococcus faecalis enhance the therapeutic efficacy of levodopa in an MPTP-induced Parkinson’s disease mouse model with E. faecalis gut colonization

  2024cites this paper
• The effect of anticholinergic drugs on cognition of patients with Parkinson’s disease: a cohort study from the Egyptian population

  2024cites this paper
• Corticostriatal beta oscillation changes associated with cognitive function in Parkinson's disease.

  2023cites this paper
• Analysis of Nucleotide Variations in Human G-Quadruplex Forming Regions Associated with Disease States

  2023cites this paper
• The dual role of striatal interneurons: circuit modulation and trophic support for the basal ganglia

  2023cites this paper
• Unraveling neurotransmitter changes in de novo GBA-related and idiopathic Parkinson's disease.

  2023cites this paper
• A review of the neurotransmitter system associated with cognitive function of the cerebellum in Parkinson’s disease

  2023cites this paper
• Pathophysiology of non-motor signs in Parkinson’s disease: some recent updating with brief presentation

  2023cites this paper
• The effects of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) on the cognitive and motor functions in rodents: A systematic review and meta-analysis.

  2022cites this paper
• The large neuron involvement in the neostriatum in Lewy body diseases

  2022cites this paper
• Distinct atrophy of septal nuclei in Parkinson’s disease

  2022cites this paper
• Objective sleep data as predictors of cognitive decline in dementia with Lewy Bodies and Parkinson's disease.

  2021cites this paper
• Interval timing and midfrontal delta oscillations are impaired in Parkinson’s disease patients with freezing of gait

  2021cites this paper
• Parkinson disease-associated cognitive impairment

  2021cites this paper
• The Cholinergic Brain in Parkinson's Disease

  2021cites this paper
• Beyond dopamine: Further evidence of cholinergic dysfunction in Parkinson's disease (Commentary on Keo et al., 2021)

  2021cites this paper
• Cognitive impairment in Parkinson's disease: A clinical and pathophysiological overview.

  2020cites this paper
• Impairment to Cognitive Functions in Wistar Rats in a Model of the Preclinical Stage of Parkinson’s Disease

  2020cites this paper
• Effects of L-DOPA on gene expression in the frontal cortex of rats with unilateral lesion of midbrain dopaminergic neurons

  2020cites this paper
• Cognition Deficits in Parkinson's Disease: Mechanisms and Treatment

  2020cites this paper
• Effects of L-DOPA on Gene Expression in the Frontal Cortex of Rats with Unilateral Lesions of Midbrain Dopaminergic Neurons

  2020cites this paper
• Cognitive Impairment in Parkinson’s Disease: What We Know so Far

  2020cites this paper
• Functional and Neuroprotective Role of Striatal Adenosine A2A Receptor Heterotetramers

  2019cites this paper
• Novel Treatment Opportunities Against Cognitive Impairment in Parkinson’s Disease with an Emphasis on Diabetes-Related Pathways

  2019cites this paper
• Cholinergic denervation in patients with idiopathic rapid eye movement sleep behaviour disorder

  2019influential citation
• Étude des bases cérébrales de la maladie à corps de Lewy par IRM multimodale

  2019cites this paper
• The Locus coeruleus in Parkinson’s disease - from basic research to new translational perspectives -

  2019cites this paper
• Revealing Adenosine A2A-Dopamine D2 Receptor Heteromers in Parkinson’s Disease Post-Mortem Brain through a New AlphaScreen-Based Assay

  2019cites this paper
• Mesencephalic and extramesencephalic dopaminergic systems in Parkinson’s disease

  2019cites this paper
• Increased Cholinergic Response in α-Synuclein Transgenic Mice (h-α-synL62).

  2018cites this paper
• The Neuroimaging of Brain Diseases: Structural and Functional Advances

  2018cites this paper
• In Vivo Positron Emission Tomography of Extrastriatal Non-Dopaminergic Pathology in Parkinson Disease

  2018cites this paper
• Mild Cognitive Impairment in Parkinson’s Disease—What Is It?

  2018cites this paper
• Wirkfluktuationen und Fieber bei Parkinson

  2018cites this paper
• Imaging the Nonmotor Symptoms in Parkinson's Disease.

  2017cites this paper
• The influence of acetylcholine, dopamine, and GABA on the functioning of the corticostriatal neuronal network in Alzheimer’s and Parkinson’s diseases: A hypothetical mechanism

  2017cites this paper
• Characterizing Cognitive Impairment in Parkinson's Disease

  2017cites this paper
• Congenital myasthenic syndrome with episodic apnoea: clinical, neurophysiological and genetic features in the long-term follow-up of 19 patients

  2017cites this paper
• Presynaptic dopaminergic terminal imaging and non-motor symptoms assessment of Parkinson’s disease: evidence for dopaminergic basis?

  2017cites this paper
• Bushen-Yizhi formula ameliorates cognitive dysfunction through SIRT1/ER stress pathway in SAMP8 mice

  2017cites this paper
• Decrease of Delta Oscillatory Responses in Cognitively Normal Parkinson’s Disease

  2017cites this paper
• Impaired cholinergic transmission in patients with Parkinson's disease and olfactory dysfunction.

  2017cites this paper
• Cholinergic/glutamatergic co‐transmission in striatal cholinergic interneurons: new mechanisms regulating striatal computation

  2017cites this paper
• Cholinergic pathology in dementia with Lewy bodies

  2017cites this paper
• Polymorphic variation in CHAT gene modulates general cognitive ability: An association study with random student cohort.

  2016cites this paper
• Enhanced Cognitive Effects of Demethoxycurcumin, a Natural Derivative of Curcumin on Scopolamine-Induced Memory Impairment in Mice

  2016cites this paper
• Mood Disorder in Parkinson's Disease

  2016cites this paper
• Lewy body dementias (DLB/PDD)

  2016cites this paper
• Neuroimaging studies of brain networks in Parkinson's disease

  2016cites this paper
• Different Functional and Microstructural Changes Depending on Duration of Mild Cognitive Impairment in Parkinson Disease

  2016cites this paper
• A study on the possible therapeutic role of Panax ginseng extract against a rat model of Parkinson’s disease induced by intrastriatal rotenone injection

  2016cites this paper
• Molecular changes in the postmortem parkinsonian brain

  2016influential citation
• Cortical Cholinergic Function Is More Severely Affected in Parkinsonian Dementia Than in Alzheimer Disease

  2015cites this paper
• Dynamic Connectivity at Rest Predicts Attention Task Performance

  2015cites this paper
• FUNCTIONAL Different Functional andMicrostructural Changes Depending on Duration ofMild Cognitive Impairment in Parkinson Disease

  2015cites this paper
• New therapeutic strategies targeting D1-type dopamine receptors for neuropsychiatric disease

  2015cites this paper
• Group comparison of spatiotemporal dynamics of intrinsic networks in Parkinson's disease.

  2015cites this paper
• Nonmotor symptoms in sporadic versus familial forms of Parkinson's disease.

  2015cites this paper
• Université de Montréal-Thèse numérique

  2014cites this paper
• Altered expression of dopamine receptors in cholinergic motoneurons of the hypoglossal nucleus in a 6-OHDA-induced Parkinson's disease rat model.

  2014cites this paper
• Where attention falls: Increased risk of falls from the converging impact of cortical cholinergic and midbrain dopamine loss on striatal function.

  2014cites this paper
• The neurobiological basis of cognitive impairment in Parkinson's disease

  2014cites this paper
• Hippocampal Lewy pathology and cholinergic dysfunction are associated with dementia in Parkinson's disease.

  2014cites this paper
• Cognitive impairment in early‐stage non‐demented Parkinson's disease patients

  2014cites this paper
• Movement Disorders Parkinson’s Disease

  2014cites this paper
• Comparison of Substantia Nigra Pars Compacta and Basal Forebrain Changes in Parkinson ’ s Disease

  2013cites this paper
• Characterization of Cognitive Deficits in Rats Overexpressing Human Alpha-Synuclein in the Ventral Tegmental Area and Medial Septum Using Recombinant Adeno-Associated Viral Vectors

  2013cites this paper
• Ascending monoaminergic systems alterations in Alzheimer's disease. translating basic science into clinical care.

  2013cites this paper
• New MRI Biomarkers Advance the Characterization of Parkinson Disease.

  2013cites this paper
• Cholinergic Dysfunction in Parkinson’s Disease

  2013cites this paper
• Exploratory analysis of neuropsychological and neuroanatomical correlates of progressive mild cognitive impairment in Parkinson's disease

  2013cites this paper
• Nonmotor Symptoms in Parkinson’s Disease

  2013cites this paper
• Substantia nigra volume loss before basal forebrain degeneration in early Parkinson disease.

  2013cites this paper
• Parkinson’s Disease Dementia

  2013cites this paper
• Verbal memory in idiopathic non-demented Parkinson's disease: A structural MRI and quantitative white matter tractography analysis

  2013cites this paper
• Management of psychosis and dementia

  2013cites this paper
• Troubles du comportement en sommeil paradoxal idiopathiques et associés à la maladie de Parkinson : analyse comportementale et neurophysiologique du traitement des informations visuelles

  2013cites this paper
• Modeling Fall Propensity in Parkinson's Disease: Deficits in the Attentional Control of Complex Movements in Rats with Cortical-Cholinergic and Striatal–Dopaminergic Deafferentation

  2013cites this paper
• Cognitive deficits in a mouse model of pre‐manifest Parkinson’s disease

  2012cites this paper
• Molecular imaging and the neuropathologies of Parkinson's disease.

  2012cites this paper
• Volumetric analysis of the substantia innominata in patients with Parkinson's disease according to cognitive status.

  2012cites this paper
• Cognitive impairment is common in Parkinson's disease without dementia in the early and middle stages in a Han Chinese cohort.

  2012cites this paper
• A three dimensional anatomical view of oscillatory resting-state activity and functional connectivity in Parkinson's disease related dementia: An MEG study using atlas-based beamforming☆

  2012cites this paper
• Neurotransmitter receptors and cognitive dysfunction in Alzheimer's disease and Parkinson's disease.

  2012cites this paper
• Brain Imaging in Behavioral Neuroscience

  2012cites this paper
• Mild cognitive impairment in Parkinson's disease.

  2011cites this paper
• A Précis of Recent Advances in the Neuropsychology of Mild Cognitive Impairment(s) in Parkinson's Disease and a Proposal of Preliminary Research Criteria

  2011cites this paper
• Cognition in healthy aging and Parkinson's disease : structural and functional integrity of neural circuits

  2011cites this paper
• Magnetic resonance imaging of cognition in Parkinson’s disease

  2011cites this paper
• The cholinergic system and Parkinson disease.

  2011cites this paper
• Neurotransmission in Parkinson’s disease: beyond dopamine

  2010cites this paper
• Olfactory dysfunction, central cholinergic integrity and cognitive impairment in Parkinson’s disease

  2010cites this paper
• Neuropsychological and clinical heterogeneity of cognitive impairment and dementia in patients with Parkinson's disease.

  2010cites this paper
• The progression of pathology in Parkinson's disease

  2010cites this paper
• Cognitive impairment and dementia in patients with Parkinson disease.

  2009cites this paper
• Dementia After Cholinesterase Inhibitor Therapy Changes in Cerebral Glucose Metabolism in Patients with Parkinson Disease with

  2008cites this paper